Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Orthocell Ltd ( (AU:OCC) ) is now available.
Orthocell Ltd, a Perth-based regenerative medicine specialist, is expanding a suite of products aimed at repairing bone, nerve, tendon and cartilage injuries, anchored by collagen medical devices and autologous cell therapies. Its lead products, including globally distributed dental membrane Striate+ and nerve repair device Remplir, have secured clearances across key markets such as the U.S., Europe, Australia and Asia, underscoring a growing international footprint.
The company has released an investor presentation to be delivered by Managing Director Paul Anderson at the WA Life Sciences Broker Meets Biotech event in Perth, highlighting its commercial momentum and development pipeline. The appearance at the broker-focused forum is poised to deepen engagement with the investment community, spotlight recent U.S. market traction for Remplir and its tendon cell therapy strategy, and potentially support future partnering and capital-raising initiatives as Orthocell consolidates its position in regenerative medicine.
The most recent analyst rating on (AU:OCC) stock is a Sell with a A$0.71 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd is an Australian regenerative medicine company focused on restoring patient mobility through products that repair bone and soft tissue injuries. Its portfolio includes collagen medical devices for dental and orthopaedic reconstruction, notably Striate+ for dental guided bone regeneration, which is cleared in major markets and globally distributed by BioHorizons Implant Systems Inc. The company also markets Remplir for peripheral nerve reconstruction, with approvals in the U.S., Australia, New Zealand, Singapore, Thailand and Canada, and is advancing SmrtGraft for tendon repair and autologous cell therapies targeting damaged tendon and cartilage tissue, including a U.S. development push for its tendon cell therapy.
Average Trading Volume: 429,127
Technical Sentiment Signal: Sell
Current Market Cap: A$203.5M
For detailed information about OCC stock, go to TipRanks’ Stock Analysis page.